Systemic priming and intranasal booster with a BcfA-adjuvanted acellular pertussis vaccine generates CD4+ IL-17+ nasal tissue resident T cells and reduces B. pertussis nasal colonization
IntroductionResurgence of pertussis, caused by Bordetella pertussis, necessitates novel vaccines and vaccination strategies to combat this disease. Alum-adjuvanted acellular pertussis vaccines (aPV) delivered intramuscularly reduce bacterial numbers in the lungs of immunized animals and humans, but...
Main Authors: | Kacy S. Yount, Jesse M. Hall, Kyle Caution, Mohamed M. Shamseldin, Myra Guo, Keirsten Marion, Audra R. Fullen, Yimin Huang, Jennifer A. Maynard, Sally A. Quataert, Rajendar Deora, Purnima Dubey |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-05-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1181876/full |
Similar Items
-
Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines
by: Susanna Esposito, et al.
Published: (2019-07-01) -
Antibody avidity to pertussis toxin after acellular pertussis vaccination and infection
by: Aapo Knuutila, et al.
Published: (2023-12-01) -
Whoop! There it is: The surprising resurgence of pertussis.
by: Audra R Fullen, et al.
Published: (2020-07-01) -
Acellular Pertussis Vaccine Components: Today and Tomorrow
by: Kalyan K. Dewan, et al.
Published: (2020-05-01) -
Bordetella pertussis Strain Lacking Pertactin and Pertussis Toxin
by: Margaret M. Williams, et al.
Published: (2016-02-01)